NCT02686593View on ClinicalTrials.gov

Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 1, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

May 1, 2018

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Clofarabine, AraC, mitoxantrone (CLAM)

The combination of clofarabine, cytarabine (Ara-C) and mitoxantrone will be used in patients with AML in first relapse or after failure of first salvage

Trial Locations (1)

Unknown

The University of Hong Kong, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT02686593 - Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML | Biotech Hunter | Biotech Hunter